It has been recognized for decades that solid tumors can contain regions at very low oxygen concentrations (hypoxia) which do not occur in normal tissues under physiological conditions. The central focus of this Program Project Grant is on this tumor hypoxia. The overall goal is to develop means to exploit in cancer treatment this key difference between tumors and normal tissues. Approximately eight years ago, we discovered a novel compound, SR 4233, which has very high selective cytotoxicity for hypoxic cells. When given appropriately with radiation or with chemotherapeutic drugs, this compound, now known as tirapazamine, can exploit the hypoxia in tumors, thereby rendering them even more sensitive to treatment than if the tumors had no hypoxic cells. This drug is now about to enter Phase II and III clinical trials. However, appropriate patient selection will be key to their success, and the first three projects in this proposal relate to various aspects of this question. The two principal questions that will be asked, with human tumor xenografts and in a clinical trial with head and neck cancers, will be first, whether the response of tumors to the addition of tirapazamine to fractionated radiation can be predicted, both from their level of hypoxia and from their cellular content of bioreductive enzymes; and second, whether the increased response of the tumors can be measured during the treatment using a surrogate, or intermediate, endpoint. Of key importance in these studies will be the appropriate measurements of tumor oxygenation, and we will investigate this with animal tumors and human tumors to determine which assay for tumor hypoxia is most accurate and most convenient for use in the clinical setting. Increasingly, hypoxia in tumors is seen as a cellular stress that can have a profound impact on the biology and progression of the tumor. Several years ago, novel proteins were identified as arising in hypoxic cells, and the last two projects focus on the cellular and molecular consequences of these proteins induced by hypoxia and/or reoxygenation of the tumor cells. These studies will be performed with cells in vitro, with cells in multicellular spheroids, and with animal and human tumors. A principal goal will be to span the gap between what is presently known about genes induced under hypoxic conditions and the significance of this for human tumors, both for their progression and for their response to treatment. This project represents a highly coordinated program between an outstanding group of investigators with expertise at the molecular, cellular, animal, and clinical levels. The group is uniquely positioned to take advantage of the latest developments in this field, including use of the hypoxic, cytotoxin, tirapazamine, use of the new commercially available oxygen polarographic electrode, and the new findings on the molecular biology of cellular hypoxia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA067166-05
Application #
6172758
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Program Officer
Stone, Helen B
Project Start
1996-06-15
Project End
2001-08-31
Budget Start
2000-04-14
Budget End
2001-08-31
Support Year
5
Fiscal Year
2000
Total Cost
$1,584,418
Indirect Cost
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Vilalta, Marta; Brune, Jourdan; Rafat, Marjan et al. (2018) The role of granulocyte macrophage colony stimulating factor (GM-CSF) in radiation-induced tumor cell migration. Clin Exp Metastasis 35:247-254
Tandon, Neha; Thakkar, Kaushik N; LaGory, Edward L et al. (2018) Generation of Stable Expression Mammalian Cell Lines Using Lentivirus. Bio Protoc 8:
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
Benej, Martin; Hong, Xiangqian; Vibhute, Sandip et al. (2018) Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci U S A 115:10756-10761
Rafat, Marjan; Aguilera, Todd A; Vilalta, Marta et al. (2018) Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients. Cancer Res 78:4241-4252
Saiki, Julie P; Cao, Hongbin; Van Wassenhove, Lauren D et al. (2018) Aldehyde dehydrogenase 3A1 activation prevents radiation-induced xerostomia by protecting salivary stem cells from toxic aldehydes. Proc Natl Acad Sci U S A 115:6279-6284
Olcina, Monica M; Kim, Ryan K; Melemenidis, Stavros et al. (2018) The tumour microenvironment links complement system dysregulation and hypoxic signalling?. Br J Radiol :20180069
Castellini, Laura; Moon, Eui Jung; Razorenova, Olga V et al. (2017) KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage. Nucleic Acids Res 45:3674-3692
VandeKopple, Matthew J; Wu, Jinghai; Baer, Lisa A et al. (2017) Stress-responsive HILPDA is necessary for thermoregulation during fasting. J Endocrinol 235:27-38
Peinado, H├ęctor; Zhang, Haiying; Matei, Irina R et al. (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17:302-317

Showing the most recent 10 out of 203 publications